|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Based on such preclinical evidence, the phase II FAME trial was designed to test the hypothesis that the addition of metformin, with or without cyclic FMD, to standard platinum-based chemotherapy improves the progression-free survival of patients with advanced, LKB-1 inactive lung adenocarcinoma.
|
30617039 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Regarding tumors arising in non-PJS patients, we recently observed that at least one-third of lung adenocarcinomas (LADs) harbor somatic LKB1 gene mutations, supporting a role for LKB1 in the origin of some sporadic tumors.
|
15077168 |
2004 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
Consistent with these findings, inactivation of LKB1 was found in 34% and 19% of 144 analysed human lung adenocarcinomas and squamous cell carcinomas, respectively.
|
17676035 |
2007 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
In the liver kinase B1 (official name STK11)-deficient mouse model, lung ADC can progressively transdifferentiate to SCC through pathologically mixed adenosquamous cell carcinoma as the intermediate status.
|
28284717 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Thus, our findings demonstrate for the first time that LKB1/STK11 inactivation is a very common event and may be integrally involved in the development of sporadic lung adenocarcinoma.
|
12097271 |
2002 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
To investigate the frequency and clinical significance of NF1 mutation, we examined mutation status of NF1, TP53, LKB1 and RB1 in 704 surgically resected lung adenocarcinomas from East Asian patients using semiconductor-based Ion Torrent sequencing platform.
|
30230541 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
AlteredExpression
|
disease |
BEFREE |
We studied gene expression profiles associated with LKB1 loss in resected lung adenocarcinomas, non-small-cell lung cancer cell lines, and murine tumors.
|
24828662 |
2014 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Collectively, our findings identify YAP as an important contributor to lung cancer progression, rationalizing YAP inhibition in the context of LKB1 deficiency as a therapeutic strategy to treat lung ADC.
|
26363011 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
The work of Skoulidis and colleagues shows that concomitant RAS and STK11/LKB1 mutations in non-small cell lung adenocarcinomas result in primary resistance to PD-1-based immunotherapy and poor T-cell infiltration.<i>Cancer Discov; 8(7); 794-6.
|
29967073 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Differential association of STK11 and TP53 with KRAS mutation-associated gene expression, proliferation and immune surveillance in lung adenocarcinoma.
|
26477306 |
2016 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
There were significantly expressed differences in the ubiquitin-related gene SH3RF1 between the LKB1 mutant and wild-type lung adenocarcinoma patients (p = 9.78013E-05).
|
30185829 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy.
|
30033530 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Wound healing assay, immunofluorescence, western blot, RT‑qPCR and IHC results for EMT‑associated markers demonstrated that a loss of fibrinogen‑like 1 (FGL1) induced EMT in LKB1 mutant lung adenocarcinoma.
|
31322182 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Genomic analysis of 14 napsin A-positive LCNECs revealed the presence of mutations typical of lung adenocarcinoma (KRAS and/or STK11) in 11 cases.
|
28884744 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results offer preclinical proof of concept for use of a Chk1 inhibitor to safely enhance the efficacy of gemcitabine, particularly in aggressive KRAS-driven LKB1-deficient lung adenocarcinomas.<i></i>.
|
28754670 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
This observation supports the hypothesis that STK11 is a tumour suppressor gene which is involved in the development of lung adenocarcinoma.
|
15639728 |
2005 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Moreover, they suggest that PIAs might have utility in the treatment of LKB1-mutant lung adenocarcinomas.
|
18199555 |
2008 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Here, we demonstrate lineage switching of KRAS+ lung adenocarcinomas (ADC) to squamous cell carcinoma (SCC) through deletion of Lkb1 (Stk11) in autochthonous and transplant models.
|
28387316 |
2017 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Liver kinase B1 (<i>LKB1</i>) is a tumor suppressor gene whose inactivation is frequent in different tumor types, especially in lung adenocarcinoma (about 30% of cases).
|
30995715 |
2019 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Exons 1, 6, and 7 of the LKB1 gene were sequenced in 174 Japanese patients with lung adenocarcinoma (including 157 men and 17 women).
|
21191700 |
2011 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Toward this end, we established stable cell lines by introducing a dominant-negative mutant of AMPK alpha1 subunit or its shRNA into the prostate cancer C4-2 cells and other cells, or wild type LKB1 into the lung adenocarcinoma A549 and breast MB-MDA-231 cancer cells, both of which lack functional LKB1.
|
19347029 |
2009 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
Somatic LKB1 mutations are present in 20.0% of lung adenocarcinomas, and we observed growth inhibition with COX-2 inhibitors in LKB1-null lung cancer cells with activated CRTC1 as compared with LKB1-wildtype cells (NS-398, P = .002 and Niflumic acid, P = .006; two-tailed t test).
|
25465874 |
2015 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
Our results identify <i>STK11/LKB1</i> alterations as a major driver of primary resistance to PD-1 blockade in <i>KRAS</i>-mutant LUAC.<b>Significance:</b> This work identifies <i>STK11/LKB1</i> alterations as the most prevalent genomic driver of primary resistance to PD-1 axis inhibitors in <i>KRAS</i>-mutant lung adenocarcinoma.
|
29773717 |
2018 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
GeneticVariation
|
disease |
BEFREE |
These results suggest that alterations of the LKB1 gene might be involved in the development of lung adenocarcinomas induced by BHP in rats.
|
20616618 |
2010 |
|
Adenocarcinoma of lung (disorder)
|
0.700 |
Biomarker
|
disease |
BEFREE |
A Sensitive NanoString-Based Assay to Score STK11 (LKB1) Pathway Disruption in Lung Adenocarcinoma.
|
26917230 |
2016 |